Restless Legs Syndrome Pipeline and Therapeutic Assessment, Drug Development by Companies Reviewed for H2 2017

Posted on 2017-07-24 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2017-Jul-24 — /EPR Network/ — While the exact numbers are not known it is thought that several million people lose sleep every night because of restless leg syndrome. Recently, increasing prevalence of this neurological disorder in the U.S. has forced the research scientists to invent effective treatment for the disease. A new study, covering the descriptive pharmacological action of the therapeutics, its complete research and development history has been published to the online repository of Market Research Hub (MRH) and titled as “Restless Leg Syndrome– Pipeline Review, H2 2017”. This study provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230568

This pipeline guide starts by presenting restless leg syndrome overview and its therapeutic development. Restless legs syndrome, also known as Willis-Ekbom disease, is a common condition of the nervous system that causes an overwhelming, irresistible urge to move the legs. It is estimated that up to 7-10 percent of the U.S. population may have RLS. It is also been examined that restless legs syndrome is one of the most common causes of insomnia. RLS occurs in both men and women, although women are more likely to have it than men. More than 80% of people with RLS also experience a common condition which is known as periodic limb movement disorder (PLMD).

Major symptoms include itching, a creepy-crawly feeling, pain and cramping in the calfs or legs. Looking to these symptoms, some people are comfortable with natural remedies for restless legs, while others prefer restless leg medication. When it comes to a restless leg syndrome treatment there are three basic approaches; muscle relaxants, narcotic and sleep medications.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/restless-legs-syndrome-pipeline-review-h2-2017-report.html

Moving further, the study offers vivid drug profiles for the pipeline products which include details such as, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. According to the research, Anti-seizure drugs are becoming the first-line prescription drugs for those with RLS. The FDA has approved gabapentin enacarbil for the treatment of moderate to severe RLS.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued project. They are as follows Galenica Ltd., Merz Pharma GmbH & Co KgaA, Serina Therapeutics Inc., Omeros Corp., Hisamitsu Pharmaceutical Co. Inc., and Mundipharma International Ltd. By the above major information, restless leg syndrome pipeline guide helps buyers in identifying and tracking emerging players in the market and their portfolios enhance policymaking capabilities and help to create effective counter-strategies to gain competitive advantage.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230568

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick